So here's a biotech story that's actually about the data, not just the stock movement. MoonLake Immunotherapeutics (MLTX) shares were doing their usual biotech dance on Monday—a little up, a little down—while the company presented some genuinely interesting long-term results for its lead drug candidate. The numbers come from the VELA-1 and VELA-2 Phase 3 trials of sonelokimab in patients with hidradenitis suppurativa (HS), a chronic inflammatory skin condition that causes painful lumps, primarily in areas like the armpits and groin. It's the kind of condition where lasting relief really matters.

The data, presented at the 2026 American Academy of Dermatology Annual Meeting, show that 62% of patients treated with sonelokimab achieved a HiSCR75 response by Week 40. For those not steeped in dermatology acronyms, that's essentially a 75% reduction in the number of painful abscesses and nodules. More importantly, it suggests the drug's effect isn't just a flash in the pan—it's durable. Even more impressive: up to 25% of patients achieved what's called inflammatory remission at Week 40, meaning a 100% reduction in abscesses, nodules, and draining tunnels. That's a big deal for a condition known for its stubborn recurrence.

But here's the part that really matters for patients: the quality-of-life improvements. We're talking about the stuff that actually changes daily living. Patients reported substantial improvements ranging from 41% in pain reduction to 54% in basic activities like walking and getting dressed, and up to 62% in feeling "down or depressed." Up to 43% of patients achieved at least a 3-point improvement in their worst skin pain. The safety profile also remained consistent, with no new red flags popping up in the extended data.

Now, the regulatory pathway is where this gets particularly interesting for investors. Back in January, MoonLake had a Type B meeting with the FDA about sonelokimab's clinical evidence strategy for HS. The agency gave what amounts to a green light for the current approach, indicating that MoonLake "may establish substantial evidence of effectiveness without additional clinical trials in HS." That's biotech-speak for "you might not need to run another expensive, time-consuming study before filing for approval." The FDA did advise that results from the VELA-2 trial should be included in the marketing application to inform safety, regardless of decisions about its utility in establishing effectiveness. MoonLake says its Biologics License Application (BLA) submission remains on track for the second half of 2026, with 52-week data from the VELA trials expected in the second quarter of that year.

Oh, and by the way—this isn't just a one-trick pony. In February, MoonLake shared topline results from its Phase 2 trial of sonelokimab in axial spondyloarthritis, a form of chronic inflammatory back pain. In that study, called S-OLARIS, 81% of patients treated with the drug achieved a clinically meaningful response at Week 12. So the molecule appears to have potential across multiple inflammatory conditions.

As for the stock? MoonLake shares were down 2.57% at $16.87 at the time of the report. But in biotech, especially with data presentations and regulatory updates, daily moves often tell you more about trader positioning than about the underlying science. The real story here is about durable efficacy, improved patient quality of life, and a regulatory path that might not require another detour through clinical trial land.